#China #Shenzhen #Metabolic Diseases #Torrey Pines #PepTetris

Torrey Pines Medicine Secures Angel Round

On July 28, 2026, Torrey Pines Medicine (Shenzhen) Ltd., a biotechnology firm focused on innovative treatments for metabolic diseases, announced that it successfully completed an angel funding round that raised tens of millions of RMB. The financing was orchestrated by Lotus Lake Capital and included contributions from various prominent investors, such as Stars Capital, Tainuo Capital, Blue Ocean Capital, and notable entrepreneur Mr. Yousheng Shen.

The funds acquired will be pivotal for Torrey Pines in its ongoing development of TPM004, an advanced ultra-long-acting peptide therapy designed to address prevalent health issues like obesity and type 2 diabetes. This financing also aims to bolster the company’s proprietary PepTetris™ peptide discovery platform, which integrates advanced engineering techniques and artificial intelligence to create novel therapeutics tailored for chronic metabolic conditions.

Dr. Qingsong Zhu, Co-founder and CEO of Torrey Pines Medicine, expressed gratitude for the investors' trust and highlighted the significant clinical challenges that remain in patient compliance and therapeutic efficacy in this sector. He conveyed the organization's commitment to utilize their proprietary platform for developing effective long-term management solutions for patients suffering from metabolic diseases.

The lead investor, Kai Guo from Lotus Lake Ventures, pointed out the crucial role of ultra-long-acting technology in improving treatment outcomes in metabolic health. According to him, Torrey Pines Medicine stands out due to its seasoned leadership team and innovative technology platform that addresses urgent medical needs. Guo affirmed the firm’s dedication to guide the company as it progresses toward clinical trials and aims for global recognition in the biotech space.

Dr. Weijun Shen, Co-founder and Chief Scientific Officer, emphasized that the next generation of peptide therapeutics demands more than merely extending the duration of drug activity. He noted the holistic approach required for optimizing molecular design, receptor pharmacology, and clinical translation, which are all critical dimensions of their development strategy. The goal is to craft molecules that offer not only prolonged therapeutic action but also optimal efficacy, safety, and dosing convenience.

In commemoration of their successful fundraising, Dr. Nieng Yan, President of the Shenzhen Medical Academy of Research and Translation (SMART), congratulated Torrey Pines Medicine and highlighted the firm’s role in supporting the convergence of foundational research and industrial translation.

About Torrey Pines Medicine

Torrey Pines Medicine is a pre-clinical-stage biotechnology company incubated by Shenzhen Bay Laboratory. The organization is committed to creating next-generation peptide therapeutics aimed at treating a range of chronic metabolic disorders, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD).

To tackle critical unmet clinical needs observed in traditional weight-loss therapies—such as gastrointestinal side effects, muscle mass reduction, and poor adherence—Torrey Pines Medicine is developing a comprehensive R&D engine focused on ultra-long-acting peptide drugs. Their innovative PepTetris™ platform utilizes AI technologies, innovative molecular engineering, and an integration of various pharmacological approaches to create therapies that require less frequent dosing without compromising effectiveness.

Their lead therapeutic candidate, TPM004, is an ultra-long-acting dual receptor agonist envisaged for clinical data release by 2027. Initial studies indicate substantial efficacy in weight management and stability in physiological environments.

Conclusion

The successful fundraising round marks a significant milestone for Torrey Pines Medicine, placing them at the forefront of peptide innovation in biotechnology. As they advance towards clinical development, their commitment to addressing metabolic diseases may provide the necessary solutions for countless patients, enhancing the therapeutic landscape for this critical area of health.